In another study of patients with lung cancer (n = 35), higher absolute count of CD303+ pDCs, and frequencies of CD303+ pDCs, CD1c+ mDCs, and CD141+ mDCs as a percentage of leukocytes prior to αPD‐1 therapy corresponded with improved clinical response. Here, CLEC4C is linked to lung cancer.